No Data
No Data
Owning 39% Shares,hedge Funds Owners Seem Interested in Immunic, Inc. (NASDAQ:IMUX),
Express News | Immunic Inc : Leerink Partners Assumes Coverage With Outperform Rating; Target Price $5
Leerink Partners Initiates Immunic(IMUX.US) With Buy Rating, Announces Target Price $5
Leerink Partners analyst Faisal Khurshid initiates coverage on $Immunic(IMUX.US)$ with a buy rating, and sets the target price at $5.According to TipRanks data, the analyst has a success rate of 90.0%
Piper Sandler Sticks to Their Buy Rating for Immunic (IMUX)
Express News | Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients With Post Covid Syndrome
Immunic Reports First Patient Enrolled in Investigator-sponsored Post-COVID Syndrome Trial | NASDAQ:IMUX